Organon is selling its JADA post-partum haemorrhage (PPH) treatment system to Laborie Medical in a deal valued at up to $465m. The US-based company will receive $440m at the deal’s closing, with ...

The JADA® System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health. Joining an ...

Organon & Co. OGN announced the completion of the divestiture of its JADA System to Laborie Medical Technologies Corp. The deal is worth up to $465 million, including $440 million paid at closing and ...

Investor AB ( ($SE:INVE.A) ) has shared an announcement. Patricia Industries’ subsidiary, Laborie, is set to acquire the JADA System from Organon, a medical device ...

Laborie Medical Technologies Corp. secured a new gem for its maternal health with the acquisition of the Jada system from Organon & Co. The terms of the deal, first announced in November, included ...

The MarketWatch News Department was not involved in the creation of this content. The acquisition expands Laborie's obstetrics portfolio and demonstrates the company's commitment to delivering ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women’s health company, today announced clearance by the U.S. Food and Drug Administration (FDA) of the Special 510(k) for ...

Please provide your email address to receive an email when new articles are posted on . The JADA system decreased abnormal postpartum uterine bleeding in vaginal and cesarean birth, regardless of ...

The MarketWatch News Department was not involved in the creation of this content. The JADA(R) System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join ...